Local Carboplatin and Radiation Therapy in the Treatment of Murine Transgenic Retinoblastoma

Murray, Timothy G.; Roth, Daniel B.; O’Brien, Joan M.; Feuer, William J.; Cicciarelli, Nicole; Markoe, Arnold M.; Hernandez, E.; Smith, Barbara J.; Windle, Jolene J.

doi:10.1001/archopht.1996.01100140585010

Cited by 37 publications

(15 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Experiments using the LH BETA T AG mouse model suggest that vascular-targeting therapy using anecortave acetate, alone or in combination with carboplatin, reduces tumor burden. 17,20 Previous studies have shown that apoptosis is a mechanism for cell death in the LH BETA T AG mouse model of retinoblastoma undergoing focal chemotherapy or vessel-targeting therapy. 21 Vascular targeting with antiangiogenic and angiostatic agents is emerging as a possible treatment option for retinoblastoma given the tumor's dependence on vascular supply and its potential to promote angiogenesis.…”

mentioning

confidence: 99%

Increased Hypoxia following Vessel Targeting in a Murine Model of Retinoblastoma

Boutrid¹,

Piña²,

Cebulla³

et al. 2009

Invest. Ophthalmol. Vis. Sci.

Self Cite

View full text Add to dashboard Cite

Treatment with a vessel-targeting agent results in changes in the tumor microenvironment as early as 1 day after treatment. By increasing hypoxia in tumors, vessel-targeting agents can be combined with glycolytic inhibitors which have been shown previously to target hypoxic regions in this transgenic model. This approach may have benefits for children with this disease and should be further investigated.

show abstract

mentioning

confidence: 99%

Increased Hypoxia following Vessel Targeting in a Murine Model of Retinoblastoma

Boutrid¹,

Piña²,

Cebulla³

et al. 2009

Invest. Ophthalmol. Vis. Sci.

Self Cite

View full text Add to dashboard Cite

show abstract

“…Due to VEGFR expression in human fetal skeletal tissues, 45 it must be noted that long-term toxicity of bevacizumab in children should be kept in mind and complications such as potential altered bone growth must be monitored. 46 In this view, it is noteworthy that various preclinical assessments have previously been reported to lead further clinical trials, such as carboplatin, which was evaluated in a subconjunctival 47 or intravitreally 48,49 route of administration. Carboplatin has also been loaded with protein nanoparticles and tested first in Rb cells 50 and a second time in patients.…”

Section: Discussionmentioning

confidence: 99%

Combination of Carboplatin and Bevacizumab Is an Efficient Therapeutic Approach in Retinoblastoma Patient-Derived Xenografts

Assayag

André

Vacher

et al. 2016

Invest. Ophthalmol. Vis. Sci.

View full text Add to dashboard Cite

show abstract

“…[23][24][25][26][27][28] Experimental advances in combined modality therapy have suggested the potential for a decrease in EBR dose when EBR is combined with ocular hyperthermia or chemotherapy. 29,30 External beam radiotherapy combined with focal salvage therapy is associated with high eye conservation and local control rates. In our series, salvage therapy was performed significantly less frequently in the RLS group compared with the MLB group, and complication rates in both groups were similar.…”

Section: Methodsmentioning

confidence: 99%

External Beam Radiotherapy in Retinoblastoma

Scott¹,

Murray

Feuer

et al. 1999

Arch Ophthalmol

View full text Add to dashboard Cite

Objective: To investigate eye conservation, local control, and complication rates among children with retinoblastoma treated with 2 different external beam radiotherapy (EBR) techniques.Methods: Fifty-eight eyes in 42 patients received EBR as the primary treatment modality for retinoblastoma (median follow-up, 37 months). The EBR technique was relative lens-sparing (RLS) in 26 eyes and modified lateral beam (MLB) in 32 eyes. Both groups were comparable in Reese-Ellsworth retinoblastoma classification. If necessary, patients received focal salvage therapy.Results: At 24 months, eye conservation rates were 88.5% and 89.1% among eyes treated with RLS and MLB, respectively (P = .40); tumor control rates without salvage therapy were 84.6% and 53.3% (P = .02), respectively. Among eyes with Reese-Ellsworth stage IV and V disease, eye conservation rates were 88% ± 8% and 83% ± 9% at 36 months in the RLS and MLB groups, respectively, and local tumor control rates were 81% ± 10% and 51% ± 12%. Percentages of eyes without cataract at 36 months were 83.1% and 63.0%, respectively (P = .40). Among patients observed for at least 18 months, midfacial hypoplasia developed in 38.5% and 29.4%, respectively (P = .70). Conclusions:The EBR technique was associated with high eye conservation and local control rates. Salvage therapy was performed significantly less frequently in the RLS group compared with the MLB group, and complication rates in both groups were similar.

show abstract

Local Carboplatin and Radiation Therapy in the Treatment of Murine Transgenic Retinoblastoma

Cited by 37 publications

References 45 publications

Increased Hypoxia following Vessel Targeting in a Murine Model of Retinoblastoma

Increased Hypoxia following Vessel Targeting in a Murine Model of Retinoblastoma

Combination of Carboplatin and Bevacizumab Is an Efficient Therapeutic Approach in Retinoblastoma Patient-Derived Xenografts

External Beam Radiotherapy in Retinoblastoma

Contact Info

Product

Resources

About